Experience. Results. Leaders.
Fresenius Health Partners (FHP) is a leader in the field of renal care; providing the right support to help people with chronic kidney disease (CKD) and end-stage renal disease (ESRD) live their lives to the fullest. Our extensive experience and expertise managing the complexities of the ESRD patient population has made us the preferred partner for government payors, private health plans, and other full risk healthcare provider organizations across the country.
Paving the way to better health outcomes through value-based care
With more than a decade of success under our belts, FHP is the recognized leader in ESRD care management, with almost 50,000 ESRD patients enrolled in our value-based care programs.
Since our inception, we have led the transition to value-based care for chronically ill patients and are in a unique position to successfully drive improvements in health outcomes. Through our unique value-based programs, we combine predictive modeling, real-time treatment monitoring and a high-touch intervention protocol to deliver the right care at the right time.
Using this approach, we have significantly reduced hospital admissions and improved patient health while reducing the cost of care.
Expert knowledge and demonstrated success
Our strategy is centered around assuming responsibility for the cost, quality and outcomes for our patients’ care. FHP brings together three components critical to the success of a value-based payment model:
Financial management — incentives and funding to drive advanced care coordination
Medical management — a 360-degree view of individual patient and population data to inform care
Care navigation — 24/7 support teams to anticipate issues before they arise and safely coordinate care at the lowest level of intensity
Combining an evidenced-based approach with an in-depth knowledge of the patient helps to create personalized treatment plans that effectively achieve our program goals. Our expertise in improving health outcomes is key to reducing the financial challenges of chronic diseases such as ESRD for both patients and payors throughout the U.S.